NanoViricides Advances Oral Gummies for Ebola Toward Phase II Trial in DRC

NanoViricides, Inc. (NYSE American: NNVC) has announced significant progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial. The trial will evaluate an oral gummies formulation for treating the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The company's proposed trial has been approved by the DRC Pillar Committee, and preparations are underway for ethics and regulatory submissions. Notably, NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited settings where infusion-based therapies are difficult to deploy. The outbreak has expanded, with 1,561 confirmed cases and 506 deaths as of July 6, and no approved treatment or vaccine exists for the Bundibugyo strain. NanoViricides believes NV-387's broad-spectrum mechanism could provide activity against multiple ebolavirus strains. The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product already shipped to the country.

NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company also develops NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir. Other drug candidates target oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. NanoViricides holds exclusive licenses from TheraCour Pharma for several antiviral drugs. The company's platform technology is based on TheraCour nanomedicine technology, licensed from AllExcel. The path to drug development is lengthy and requires substantial capital, with no assurance of success.

The news release was disseminated by InvestorWire, a specialized communications platform for press release syndication. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, offering access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and corporate communications solutions. For more information, visit www.InvestorWire.com.